KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
about
Opportunities and limitations of natural killer cells as adoptive therapy for malignant diseaseThe favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid LeukemiaSpecific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsActivating killer cell Ig-like receptors in health and disease.Novel immune modulators used in hematology: impact on NK cellsHunting for clinical translation with innate-like immune cells and their receptors.Immunology and immunotherapy of chronic myeloid leukemia.Response-related predictors of survival in CML.Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.Chronic myeloid leukemia: First-line drug of choice.Regulation of Hematopoiesis and Hematological Disease by TGF-β Family Signaling Molecules.Peptide-specific engagement of the activating NK cell receptor KIR2DS1.Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
P2860
Q34307792-78E64883-1C58-427A-84EE-8CAE6CF00153Q36691438-D04357B4-F8C3-416A-BB90-756013EB91A5Q37024340-04B3493E-D3B1-4DCB-9EB3-1DBA6E649CDAQ37097120-7AC50DB9-FEE6-405C-AEE7-712E7ECDD5F3Q37509428-98ACC9E0-E8D2-4C6C-9966-ED3B9554856CQ37725657-5E7E9874-90DA-44CC-B099-E87227B5A3D3Q38073760-E0A84448-A5B0-4F9F-9C30-FCFCB5E0CE64Q38171917-4CE03874-57CB-4CD9-8FC8-03D7A3E931E5Q38175864-49986A8C-AC55-4095-94FE-1E75212AFEC8Q38392705-D505DF2D-78F0-49AD-8E88-54B453205215Q38404422-D07C1E21-8119-4802-B5CD-D7CA22F3F2BEQ38685803-7D9DAB9A-E056-4A17-8382-E3A3C4E4B64DQ38697314-937CF89C-3D49-40AA-8585-723E62278FF2Q39134073-C71FEFB6-75E1-413B-9B65-0D0FB1D00407Q40184605-1C612F88-9643-45FB-8B4E-0DDA77E6E1AFQ54495485-5FA36E25-69B1-4F70-A2EA-45404831B55A
P2860
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
KIR2DS1 genotype predicts for ...... atients treated with imatinib.
@en
KIR2DS1 genotype predicts for ...... atients treated with imatinib.
@nl
type
label
KIR2DS1 genotype predicts for ...... atients treated with imatinib.
@en
KIR2DS1 genotype predicts for ...... atients treated with imatinib.
@nl
prefLabel
KIR2DS1 genotype predicts for ...... atients treated with imatinib.
@en
KIR2DS1 genotype predicts for ...... atients treated with imatinib.
@nl
P2093
P2860
P356
P1433
P1476
KIR2DS1 genotype predicts for ...... atients treated with imatinib.
@en
P2093
A Alsuliman
D Milojkovic
H de Lavallade
I H Gabriel
J F Apperley
J M Goldman
P2860
P2888
P304
P356
10.1038/LEU.2011.180
P577
2011-08-16T00:00:00Z